An observational study in Keratoconus, sponsored by Suphi Taneri. Active, not recruiting at 2 sites in Germany. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Suphi Taneri · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Corneal Cross Linking is new treatment modality for patients with keratoconus. A keratoconus is characterized by progressive bulging and thinning of the eye's cornea. Keratoconus is a potentially severely sight impairing condition that may necessitate corneal transplantation in the progressive state.
Corneal Cross Linking is designed to
Corneal Cross Linking is performed by
This register of Corneal Cross Linking procedures performed in Germany serves to
313 studies on the registry are indexed under Keratoconus; 55 are open to participants now.
This study's enrollment of 356 is above the median of 130 across 97 observational studies indexed under Keratoconus.
Browse Keratoconus studies →Suphi Taneri is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients treated with Corneal Cross Linking in Germany
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cross linked eyes
Procedure: CCL (Corneal Cross Linking)
Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance
Also known as: Collagen cross linking, Corneal collagen cross linking, CCL, 3C-L
Visual Acuity
Corrected Visual Acuity after crosslinking at the latest follow up examination
Time frame: 172 to 3396 days
Postoperative K Max
K max after Crosslinking
Time frame: 172 to 3396 days
Sphere
Sphere values after crosslinking at lastest-follow-up
Time frame: 172 to 3396 days
Cylinder
Refractive cylinder after Crosslinking at latest follow-up
Time frame: 172 to 3396 days
Endothelial Cell Density
Endothelial cell density after Crosslinking at latest follow-up
Time frame: 172 to 3396 days
All eyes included with corneal crosslinking
| Milestone | PRK CXL | PTK CXL | Manual CXL |
|---|---|---|---|
| Started | 49 | 149 | 158 |
| Completed | 49 | 149 | 158 |
| Not completed | 0 | 0 | 0 |
Corrected Visual Acuity after crosslinking at the latest follow up examination
| letters read per line | PRK CXL | PTK CXL | Manual CXL |
|---|---|---|---|
| Visual Acuity | 0.85 ± 0.33 | 0.83 ± 0.36 | 0.79 ± 0.35 |
K max after Crosslinking
| Diopters | PRK CXL | PTK CXL | Manual CXL |
|---|---|---|---|
| Postoperative K Max | 49.37 ± 4.59 | 49.9 ± 4.85 | 52.36 ± 5.05 |
Sphere values after crosslinking at lastest-follow-up
| Diopters | PRK CXL | PTK CXL | Manual CXL |
|---|---|---|---|
| Sphere | 0.5 ± 2.21 | -0.06 ± 2.72 | -0.87 ± 2.16 |
Refractive cylinder after Crosslinking at latest follow-up
| Diopters | PRK CXL | PTK CXL | Manual CXL |
|---|---|---|---|
| Cylinder | -1.5 ± 1.17 | -2.23 ± 1.92 | -2.16 ± 1.78 |
Endothelial cell density after Crosslinking at latest follow-up
| Cells/mm^2 | PRK CXL | PTK CXL | Manual CXL |
|---|---|---|---|
| Endothelial Cell Density | 2886 ± 264 | 2841 ± 311 | 2786 ± 274 |
Collected over Up until 3 month post corneal crosslinking. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PRK CXL | 0/33 (0%) | 0/33 (0%) | 6/33 (18.2%) |
| PTK CXL | 0/70 (0%) | 0/70 (0%) | 5/70 (7.1%) |
| Manual CXL | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| Event | PRK CXL | PTK CXL | Manual CXL |
|---|---|---|---|
| Sterile InfiltratesEye disorders | 6/33 | 5/70 | 0/20 |
| Age, Categorical(Participants) | PRK CXL | PTK CXL | Manual CXL | Total |
|---|---|---|---|---|
| <=18 years | 4 | 24 | 32 | 60 |
| Between 18 and 65 years | 45 | 125 | 126 | 296 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | PRK CXL | PTK CXL | Manual CXL | Total |
|---|---|---|---|---|
| Female | 11 | 32 | 32 | 75 |
| Male | 38 | 117 | 126 | 281 |
| Race and Ethnicity Not Collected(Participants) | PRK CXL | PTK CXL | Manual CXL | Total |
|---|---|---|---|---|
| Count of participants | — | — | — | 0 |
| Corrected Visual Acuity(letters read per line) | PRK CXL | PTK CXL | Manual CXL | Total |
|---|---|---|---|---|
| Geometric mean | 0.7 ± 0.35 | 0.61 ± 0.35 | 0.41 ± 0.28 | 0.67 ± 0.36 |
| Sphere(Diopters) | PRK CXL | PTK CXL | Manual CXL | Total |
|---|---|---|---|---|
| Mean | -0.29 ± 3.17 | -0.4 ± 3.48 | -1.95 ± 3.33 | -0.88 ± 4.38 |
| Cylinder(Diopters) | PRK CXL | PTK CXL | Manual CXL | Total |
|---|---|---|---|---|
| Mean | -2.96 ± 1.79 | -2.90 ± 2.28 | -2.04 ± 4.52 | -2.63 ± 3.12 |
| Endothelial Cells(cells/mm^2) | PRK CXL | PTK CXL | Manual CXL | Total |
|---|---|---|---|---|
| Mean | 2866 ± 271 | 2796 ± 284 | 2834 ± 339 | 2818 ± 351 |
| K1(Diopters) | PRK CXL | PTK CXL | Manual CXL | Total |
|---|---|---|---|---|
| Mean | 45.11 ± 3.02 | 44.29 ± 3.93 | 49.7 ± 11.09 | 44.81 ± 3.98 |
4 further baseline measures are reported on the registry.
Ran from Nov 2007 to primary completion in Nov 2024, 204 months.
Results were first posted in Jun 2026, 1 year 7 months after primary completion.
Of 33 non-industry observational studies under Keratoconus, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 204. This study's 204 months is above that.
Counting every sponsor, half of 36 studies reached it within 30 months; a quarter within 13 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Suphi Taneri